Antithymocyte immunoglobulin (rabbit)
- Generic Name
- Antithymocyte immunoglobulin (rabbit)
- Drug Type
- Biotech
- CAS Number
- 308067-60-9
- Unique Ingredient Identifier
- D7RD81HE4W
- Background
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
- Indication
For prevention of renal transplant rejection
- Associated Conditions
- Rejection Acute Renal
SAB-142 Shows Promise in Phase 1 Trial for Type 1 Diabetes
• SAB BIO's SAB-142 demonstrated a favorable safety profile in a Phase 1 trial, supporting chronic dosing in an outpatient setting.
• The Phase 1 trial of SAB-142 showed clinically validated multi-target immunomodulation, analogous to rabbit ATG.
• SAB BIO plans to advance SAB-142 into a Phase 2b trial in 2025 to evaluate its therapeutic potential in patients with new-onset T1D.
• Topline data from the Phase 1 trial supports SAB-142's potential as a transformative therapy for delaying the progression of type 1 diabetes.
Sanofi's Q3 Sales Surge 15.7% Driven by Vaccines and Dupixent; 2024 EPS Guidance Raised
• Sanofi reported a robust 15.7% sales growth in Q3, fueled by strong vaccine sales and the continued success of Dupixent, with sales up 23.8% to €3,476 million.
• Pharma launches, including ALTUVIIIO, Nexviazyme, and Rezurock, saw a significant 67.1% increase, contributing €727 million to the overall sales growth.
• The company's pipeline advanced with four regulatory approvals, including Dupixent for COPD in the US and China, and four positive Phase 3 data readouts, including tolebrutinib for nrSPMS.
• Based on strong Q3 business performance, Sanofi has raised its 2024 business EPS guidance to at least a low single-digit percentage growth at CER.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath